Anthracycline-refractory TNBC
1 clinical trials · Condition
◉ Watch Anthracycline-refractory TNBC
| Record | Firm | Date |
|---|---|---|
| Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer (NCT04095689) | The Methodist Hospital Research Institute | 2021-05-12 |
Track Anthracycline-refractory TNBC automatically
Every clearance here is in the API, with alerts when new ones post.